Carl H. June

This paper develops a framework to engineer oncolytic vaccinia virus to support off-the-shelf NK cells by aligning viral payloads with NK cell manufacturing limitations.

The paper develops a system to create binders compatible across HLA allotypes, validated against clinically relevant antigens and demonstrated in CAR T cells.

This paper develops a bioinspired oxidized lipid nanoparticle platform for mRNA-based engineering of CAR-Ms to target solid tumors, showing improved delivery and tumor-killing efficacy.

This study shows that adding IL-9 signaling to CAR T cells improves their anti-tumor effectiveness by shifting their fate toward memory and cycling states.

This paper develops a CAR T-cell targeting the mesothelin stump domain, showing comparable cytotoxicity and effectiveness against resistant tumors compared to standard anti-mesothelin CAR T-cells.

This study develops DR5-targeted CAR-T cells that kill solid tumors and MDSCs, enhance CD8+ T cell activity, and show minimal toxicity in preclinical models.

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

This study shows that IL18-expressing CAR T cells enhance antitumor immunity, T cell proliferation, and costimulation, while reducing GVHD risk through a novel strategy.